• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • hRPCs for Retinal Disease
    • CTX cells for Stroke Disability
    • CTX-derived Exosomes
    • Induced pluripotent stem cell (iPSC) Platform
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I/IIa clinical trial in retinitis pigmentosa
    • Phase IIb Clinical trial in stroke disability (PISCES III)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Phase I clinical trial in stroke disability (PISCES)
    • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Products
    • Our Products & Technologies
    • hRPCs for Retinal Disease
    • CTX cells for Stroke Disability
    • CTX-derived Exosomes
    • Induced pluripotent stem cell (iPSC) Platform
    • ReNcell Products
    • Publications
  • Clinical Trials
    • Clinical Trials
    • Phase I/IIa clinical trial in retinitis pigmentosa
    • Phase IIb Clinical trial in stroke disability (PISCES III)
    • Phase IIa clinical trial in stroke disability (PISCES-II)
    • Phase I clinical trial in stroke disability (PISCES)
    • Observational study in stroke
  • News
    • News Centre
    • News
    • Events
    • Media Coverage
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Webcasts and Presentations
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Pioneering stem cell therapeutics

We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Please click here for documents relating to the 2020 Placing, Subscription and Open Offer

Learn More About ReNeuron

Latest News

View all

Clinical update

Analyst Conference Call

Notification of Allowance granted for US patent

Result of General Meeting and Total Voting Rights

Result of Open Offer

Share Price

More details

125.5p 0.500p

at 24-01-2021 7:37:00

15 minute delayed share price from London Stock Exchange provided by Euroland.

Share Price

More details

125.5p 0.500p

at 24-01-2021 7:37:00

15 minute delayed share price from London Stock Exchange provided by Euroland.

Our Products & Technologies

Lab working look at petri dish Read more

Clinical Trials

hRPCs for Retinitis Pigmentosa Read more

Investor Centre

Investor Centre banner image Read more

Subscribe here for our Press Releases:

The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: 

© ReNeuron Group plc 2021 All rights reserved

Website design by Carr Kamasa Design

  • Privacy Notice
  • Disclaimer